ABSTRACT
The substantial individual heterogeneity that characterizes mental illness is often ignored by classical case-control designs that rely on group mean comparisons. Here, we present a comprehensive, multiscale characterization of individual heterogeneity of brain changes in 1294 cases diagnosed with one of six conditions and 1465 matched healthy controls. Normative models identified that person-specific deviations from population expectations for regional grey matter volume were highly heterogeneous, affecting the same area in <7% of people with the same diagnosis. However, these deviations were embedded within common functional circuits and networks in up to 56% of cases. The salience/ventral attention system was implicated transdiagnostically, with other systems selectively involved in depression, bipolar disorder, schizophrenia, and ADHD. Our findings indicate that while phenotypic differences between cases assigned the same diagnosis may arise from heterogeneity in the location of regional deviations, phenotypic similarities are attributable to dysfunction of common functional circuits and networks.
Competing Interest Statement
KA is a scientific advisor to and shareholder in BrainKey Inc., a medical image analysis software company. BF has received educational speaking fees from Medice GmbH. CFB is director and shareholder of SBGNeuro Ltd. OAA is a consultant to HealthLytix and received speakers honorarium from Lundbeck and Sunovion. MY has received philanthropic donations from the David Winston Turner Endowment Fund, Wilson Foundation, as well as payments in relation to court-, expert witness-, and/or expert review-reports. Finally, he has received funding to conduct sponsored Investigator-Initiated trials (including Incannex Healthcare Ltd). These funding sources had no role in the design, management, data analysis, presentation, or interpretation and write-up of the data. MY also sits on the Advisory Boards of Centre of The Urban Mental Health, University of Amsterdam; Enosis Therapeutics; and Monash Biomedical Imaging Centre. MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Abbot, Astra Zeneca, Janssen and Janssen, Lundbeck and Merck and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Eisai, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier - all unrelated to this work. MB has received grant/research support from National Health and Medical Research Council, Wellcome Trust, Medical Research Future Fund, Victorian Medical Research Acceleration Fund, Centre for Research Excellence CRE, Victorian Government Department of Jobs, Precincts and Regions and Victorian COVID-19 Research Fund. He received honoraria from Springer, Oxford University Press, Cambridge University Press, Allen and Unwin, Lundbeck, Controversias Barcelona, Servier, Medisquire, HealthEd, ANZJP, EPA, Janssen, Medplan, Milken Institute, RANZCP, Abbott India, ASCP, Headspace and Sandoz. The other authors report no conflicts of interest.
Funding Statement
This work was supported by the MASSIVE HCP facility (http://www.massive.org.au). This study was supported by the Australian Schizophrenia Research Bank (ASRB), which is supported by the National Health and Medical Research Council of Australia, the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. This research was supported by grants from the European Research Council (ERC, grant 'MENTALPRECISION' 10100118 and 'BRAINMIN' 802998), the Wellcome Trust under an Innovator award ('BRAINCHART,' 215698/Z/19/Z) and a Strategic Award (098369/Z/12/Z), the Dutch Organisation for Scientific Research (VIDI grant 016.156.415) the Research Council of Norway (223273, 249795, 298646, 300768, and 276082), the South-Eastern Norway Regional Health Authority (2014097, 2015073, 2016083, and 2019101), the Carlos III Heath Institute (PI16/00889 and PI19/01171), the Generalitat de Catalunya (PERIS grant SLT006/17/00249). The work was also supported by grant U54 EB020403 to the ENIGMA Consortium from the BD2K Initiative, a cross-NIH partnership, and by the European College of Neuropsychopharmacology (ECNP) Network "ADHD Across the Lifespan", and by the Australian National Health and Medical Research Council of Australia (NHMRC) Project Grants 1024570 (principal investigator, CGD) and 1064643 (principal investigator, BJH). LP was supported by the National Institute Of Mental Health of the National Institutes of Health under Award Number K99MH127296 and a 2020 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. TW gratefully acknowledges the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 895011. BF is supported by a personal Veni grant from the Netherlands Organization for Scientific Research (NWO, grant number 016-130-669). MH is supported by a personal Veni grant from the Netherlands Organization for Scientific Research (NWO, grant number 91619115). AZ was supported by a research fellowship from the NHMRC (APP1118153). CGD and BJH were supported by NHMRC Career Development Fellowships (1141738 and 1124472, respectively). JT was supported by the Turner Impact Fellowship from the Turner Institute for Brain and Mental Health. MY role on this paper was funded through a National Health and Medical Research Council Fellowship (NHMRC; #APP1117188). MY also receives funding from other NHMRC schemes, Monash University, and Australian Government funding bodies such as the Australian Research Council (ARC), Australian Defence Science and Technology (DST), and the Department of Industry, Innovation and Science (DIIS). MB was supported by a NHMRC Senior Principal Research Fellowship (1156072). SC was supported by a NHMRC Senior Research Fellowship (APP1136344). MAB was supported by National Health and Medical Research Council (Senior Research Fellow - Level B). AF was support by the Sylvia and Charles Viertel Foundation, National Health and Medical Research Council (IDs: 1197431, 1146292, and 1050504) and Australian Research Council (ID: DP200103509). We would like to thank Seghier, M. L for sharing code to generate threshold-weighted overlap maps. We would like to thank all the sites and investigators who have worked to share their data through data sharing repositories including ABIDE and OpenNeuro. Additional data were provided [in part] by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethics committee of each dataset, and written informed consent was obtained from each participant. This study was approved by the Monash University Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data for the ABIDE studies are available online at http://fcon_1000.projects.nitrc.org/indi/abide/. Raw data for the ASRB study is available in the ASRB repository, subject to the approval of the ASRB Access Committee https://www.neura.edu.au/discovery-portal/asrb/. Raw data from the FEMS, MON, OCDPG, SPAINOCD, and YoDA studies are available from the principal investigator of the dataset, subject to local ethics committee requirements. Raw data from the KANMDD, MITASD, RUSMDD, WASHASD studies are available from the OpenNeuro repository. Raw data for the HCP study is available online at https://www.humanconnectome.org/study/hcp-young-adult. Raw data for IMpACT-NL and TOP15 are not publicly available due to privacy or ethical restrictions.
